Bayer, a global leader in radiology, announced positive results from the phase III study QUANTI CNS, which evaluated the investigational gadolinium-based contrast agent (GBCA) gadoquatrane in adults ...

QUANTI CNS is part of Bayer’s pivotal QUANTI clinical development program consisting of two multinational Phase III studies in adults as well as a pediatric study. In all studies, gadoquatrane ...

Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025: Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III ...

Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III results from the clinical development program QUANTI on investigational MRI contrast ...

Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III results from the clinical development program QUANTI on investigational MRI contrast agent ...

Gadoquatrane offers an opportunity to help achieve that objective and – in the first phase 3 trial from Bayer's QUANTI programme – has shown it is at least as effective as current GBCAs ...

Bayer, a global leader in radiology, announced positive results from the Phase III study QUANTI CNS, which evaluated the investigational gadolinium-based contrast agent (GBCA) gadoquatrane in ...